Pfizer and Astellas' Xtandi fails in late-stage cancer trial v Zytiga

15 December 2016

US pharma giant Pfizer (NYSE:PFE) and Japan's Astellas (TSE:4503) have announced that treatment with Xtandi (enzalutamide), plus Zytiga (abiraterone acetate) and the steroid treatment prednisone failed to best treatment with the latter two drugs alone in a Phase IV PLATO trial in extending progression-free survival in prostate cancer patients.

The drug was tested in addition to the steroid, plus Johnson & Johnson's (NYSE: JNJ) Zytiga in 509 sufferers of metastatic castration-resistant prostate cancer (CRPC) who had not received chemotherapy. The patients were previously treated with Xtandi until their cancer progressed.

"We are committed to continuing to explore the clinical potential of Xtandi across the disease continuum"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK